ReviewJournal of the National Cancer Institute. Monographs2010
Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective.
Review in Journal of the National Cancer Institute. Monographs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis.BMC cancer · 2015Pooled it
- DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Guideline
- Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes.Oncotarget · 2017Observational
- Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.Breast cancer research and treatment · 2016Article
- Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.Clinics (Sao Paulo, Brazil) · 2013Article
- Role of the radiotherapy boost on local control in ductal carcinoma in situ.International journal of surgical oncology · 2012Article
- Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Four randomized clinical trials have shown unanimously the benefit of 50 Gy whole-breast radiotherapy in breast-conserving therapy (BCT) for ductal carcinoma in situ (DCIS). The risk of both DCIS and invasive local recurrence is reduced with about 50%, and this effect is similar for all clinical and histological subgroups analyzed. Younger age and involved margin status are the most important factors for an increased risk of local recurrence. In these subgroups, even with radiotherapy, the observed local recurrence rates are more than 20% at 10 years, which is considerably higher than reported local recurrence rates after BCT for invasive breast cancer. The optimal radiotherapy dose in BCT for DCIS has yet to be established. Also, at present, a subgroup of lesions in which the recurrence rate is so low that radiotherapy can be safely omitted has not yet been identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.